- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05868486
Analys av helkroppsmagnetresonanstomografi och vätskebiopsi för tidig upptäckt av cancer hos patienter med en stark familjehistoria av cancer
Helkropps-MR och flytande biopsi för tidig upptäckt av cancer
This study evaluates patient acceptability of whole body magnetic resonance imaging (WBM) and liquid biopsies (LB) in detecting early stage cancer in patients with a strong family history of cancer. Collecting family history and testing for genes passed on from parent to child (germline testing) can be used to predict the likelihood of a patient developing cancer. Currently, detection of early cancers focuses on screening specific organ systems such as breast and colon cancer. Magnetic resonance imaging (MRI) uses a large magnet and radio waves to look at organs and structures inside the body. Health care professionals use MRI scans to diagnose a variety of conditions, from torn ligaments to cancer. Liquid biopsy is test that analyzes blood samples to determine if cancer cells are present. This study may help researchers determine the feasibility of WBM and liquid biopsies to detect early stage cancer in patients that have a strong family history of cancer.
Studieöversikt
Status
Detaljerad beskrivning
PRIMARY OBJECTIVE:
I. To assess the acceptability of the approach of LB and WBM.
SECONDARY OBJECTIVES:
I. Determine the prevalence of WBM findings requiring additional imaging or invasive testing.
II. Determine the effect of germline testing, LB, and WBM on psychological distress and health-related quality of life (HR-QOL) at 6 months after testing compared with baseline.
EXPLORATORY OBJECTIVE:
I. Determine correlation between high-risk LB findings and cancer detected on WBM.
OUTLINE: This is an observational study.
Patients undergo WBM without contrast, blood sample collection for liquid biopsy, and complete surveys on study. Germline testing may also be performed on blood sample collected as standard of care or using the Precision Medicine protocol (Institutional Review Board [IRB] 96144).
Studietyp
Inskrivning (Faktisk)
Fas
- Tidig fas 1
Kontakter och platser
Studieorter
-
-
California
-
Duarte, California, Förenta staterna, 91010
- City of Hope Medical Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age >= 50 years, or age within 10 years of first degree relative with cancer at age of diagnosis (as long as age is >= 18)
- Have a strong family history of cancer ( >= 2 first-degree relatives with cancer, one first and second degree relative with cancer in one lineage (side of family), or at least three first or second degree relatives with cancer in one lineage (side of the family). Non-melanoma skin cancer excluded from family history eligibility
- Have a family history of early-onset cancer (age >40) in at least one first-degree relative
- Willing to have 50 mL of blood (approximately 3.5 tablespoons) drawn (40 ml if germline testing already performed)
- Able to undergo MRI (no implants, metal, or claustrophobia that would preclude MRI)
- Any cancer diagnosis within past 5 years, excluding non-melanoma skin cancer
- Positron emission tomography/computed tomography (PET/CT) or other whole body imaging modality (including combination of CT chest and abdomen) within 3 years
- No signs/symptoms of possible cancer (e.g. hemoptysis, breast mass, blood per rectum, unexplained weight loss)
- Willing to undergo standard of care genetic counseling and germline testing, or has already undergone genetic counseling and germline testing
- Documented informed consent of the participant
Exclusion Criteria:
- Unable to provide informed consent
- Contraindications to MRI (implants, metal, or claustrophobia that would preclude MRI)
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Undersökning
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Whole Body MRI and Liquid Biopsy
Patients undergo WBM without contrast and blood sample collection for liquid biopsy |
Undergo blood sample collection
Andra namn:
Complete surveys Undergo germline testing
Andra namn:
Undergo liquid biopsy testing
Andra namn:
Undergo whole body MRI without contrast
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Acceptability of germline testing, liquid biopsy and whole body magnetic resonance imaging (WBM)
Tidsram: Up to 6 months after WBM
|
Acceptability, as measured by the survey question "How satisfied are you with the research study overall?" and is defined as a score of 4 ("moderately acceptable) or 5 ("highly acceptable"). |
Up to 6 months after WBM
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Prevalence of WBM findings requiring additional imaging or invasive testing
Tidsram: Up to 6 months after WBM
|
Prevalence of WBM findings requiring additional imaging or invasive testing, described as a per participant percentage. |
Up to 6 months after WBM
|
|
Psychological distress (Germline testing)A
Tidsram: Up to 6 months after WBM
|
The effect of germline testing on psychological distress, as measured by STAI survey composite score between baseline and 6 months after testing. |
Up to 6 months after WBM
|
|
Psychological distress (Germline testing)B
Tidsram: Up to 6 months after WBM
|
The effect of germline testing on psychological distress, as measured by cancer worry scale survey scores between baseline and 6 months after testing. |
Up to 6 months after WBM
|
|
Psychological distress (Liquid Biopsy)A
Tidsram: Up to 6 months after WBM
|
The effect of LB on psychological distress, as measured by STAI survey composite score between baseline and 6 months after testing. |
Up to 6 months after WBM
|
|
Psychological distress (Liquid Biopsy)B
Tidsram: Up to 6 months after WBM
|
The effect of LB on psychological distress, as measured by cancer worry scale survey scores between baseline and 6 months after testing. |
Up to 6 months after WBM
|
|
Psychological distress (WBM)A
Tidsram: Up to 6 months after WBM
|
The effect of Whole Body MRI on Psychological distress, as measured by STAI survey composite score between baseline and 6 months after testing. |
Up to 6 months after WBM
|
|
Psychological distress (WBM)B
Tidsram: Up to 6 months after WBM
|
The effect of Whole Body MRI on Psychological distress, as measured by cancer worry scale survey scores between baseline and 6 months after testing. |
Up to 6 months after WBM
|
|
Health Related Quality of Life (HRQOL/Germline)
Tidsram: Up to 6 months after WBM
|
The effect of germline testing on HRQOL, as measured by the change in SF12 survey composite score between baseline and 6 months after testing. |
Up to 6 months after WBM
|
|
Health Related Quality of Life (HRQOL/LB)
Tidsram: Up to 6 months after WBM
|
The effect of LB on HRQOL, as measured by the change in SF12 survey composite score between baseline and 6 months after testing. |
Up to 6 months after WBM
|
|
Health Related Quality of Life (HRQOL/WBM)
Tidsram: Up to 6 months after WBM
|
The effect of WBM on HRQOL, as measured by the change in SF12 survey composite score between baseline and 6 months after testing. |
Up to 6 months after WBM
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Correlation between high-risk liquid biopsy findings and cancer detected on WBM
Tidsram: Up to 6 months after WBM
|
Liquid biopsy (LB) test sensitivity and specificity calculated by comparing the LB results with the WBM results, with WBM results considered the gold standard. Confusion matrix statistics, such as positive predictive value, negative predictive value, and test accuracy examined. Results reported with their corresponding 95% confidence intervals. |
Up to 6 months after WBM
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Dan Raz, City of Hope Medical Center
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Undersökningstekniker
- Kliniska laboratorietekniker
- Diagnostiska tekniker och procedurer
- Diagnos
- Cytologiska tekniker
- Biopsi
- Cytodiagnos
- Farmakologiska åtgärder
- Kemiska åtgärder och användningar
- Vårdtjänster
- Sjukvårdsanläggningar och tjänster
- Gemenskapens hälsovård
- Förebyggande hälsovårdstjänster
- Beteendediscipliner och aktiviteter
- Specialanvändning av kemikalier
- Mentalvårdstjänster
- Genetiska tekniker
- Genetiska tjänster
- Diagnostiska tjänster
- Diagnostisk användning av kemikalier
- Flytande biopsi
- Provhantering
- Genetisk testning
- Rådgivning
- Kontrastmedium
Andra studie-ID-nummer
- 21574
- P30CA033572 (U.S.S. NIH-anslag/kontrakt)
- 21574 (Annan identifierare: City of Hope Medical Center)
- NCI-2022-01829 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .